Financial Gravity Asset Management, Inc. Inhibrx, Inc. Transaction History

Financial Gravity Asset Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jun 26, 2024	SELL	$32.76 - $39.56 $65 - $79	-2 Reduced 50.0%	2 $73,000
Q1 2024 May 13, 2024	BUY	$32.76 - $39.56 $98 - $118	3 Added 300.0%	4 $159,000
Q3 2023 Nov 15, 2023	SELL	$15.75 - $26.31 $393 - $657	-25 Reduced 96.15%	1 $0
Q2 2023 Aug 08, 2023	BUY	$16.96 - $27.82 $440 - $723	26 New	26 $40,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $550M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.